4202-Hvs-101- A Randomized, Placebo-Controlled, Double Blind, Single Ascending And Multiple Ascending Dose Study To Assess The Safety, Pharmacokinetics And Pharmacodynamics Of Ft-4202 In Healthy Volunteers And Sickle Cell Disease Patients.
Posted Date: Nov 7, 2019
- Investigator: Hyon Kim
- Type of Study: Drug
The goal of this study is to evaluate the safety and tolerability of a single ascending dose and multiple ascending doses of FT-4202 in healthy volunteers and sickle cell disease (SCD) patients.
Criteria:
To Be Eligible: Nonpregnant/Nonbreastfeeding, No Hiv Or Hepatitis, 12-50 Yrs Of Age, >40Kg, Systolic Bp 90-150 Mmhg, Diastolic 50-95 Mmhg, No Severe Co-Morbitities
Keywords:
Sickle Cell
For More Information:
Uc Cancer Center
513-584-7698
cancer@uchealth.com